Compare Ascendis Pharma A/S (ASND) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Nasdaq Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Nasdaq Inc trades at $88.08 (market cap $49.81B). The key difference: Nasdaq Inc is far larger — about 2.8× Ascendis Pharma A/S's market cap, and Nasdaq Inc pays a 1.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NDAQ | |
|---|---|---|
Market Cap | $17.74B | $49.81B |
Sector | Health | Financials |
52-Week High | $277.18 | $100.98 |
52-Week Low | $163.32 | $76.85 |
Enterprise Value | $18.11B | $56.88B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Nasdaq (NDAQ) trades at $88.08, up 0.64% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. Revenue grew to $8.26 billion in 2025, with net income margin expanding to 23.03%. The stock shows robust institutional support, with 61% of analysts rating it a Buy and a consensus price target of $105.60, indicating ~20% upside potential.
Outlook remains positive given Nasdaq's dominant market position and exposure to capital markets growth, though risks include high valuation multiples (P/E 26.53) and sensitivity to equity market volatility. The stock's recent strength near resistance at $89 may prompt consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
